The AI in Drug Repurposing market is rapidly emerging as a game-changer in the healthcare and pharmaceutical landscape, with the global market projected to reach USD 6.29 billion by 2034, expanding at a robust 20.1% CAGR from 2025 to 2034, according to the latest Polaris Market Research report “AI In Drug Repurposing Market Size, Share, Trends, Industry Analysis Report.”

This explosive growth underscores the critical role of artificial intelligence (AI) in accelerating drug discovery timelines, reducing R&D costs, and identifying new therapeutic potentials for existing drugs — a process traditionally fraught with years of research and billions in spending. AI-enabled drug repurposing solutions are redefining how pharmaceutical organizations and research institutions tackle chronic, rare, and complex diseases.

AI in Drug Repurposing Market: Driving Breakthroughs in Healthcare Innovation

The AI in Drug Repurposing market’s ascendancy is powered by significant technological advancements in machine learning, deep learning, and predictive analytics — all of which enhance drug-target interaction predictions and uncover novel indications for established molecules. These breakthroughs are enabling clinical and biomedical researchers to streamline discovery pipelines, mitigate regulatory risks, and deliver lifesaving therapies faster than ever before.

Key Market Drivers Include:

• Increasing Prevalence of Chronic and Rare Diseases: The rising global burden of complex health conditions is pushing pharma companies to adopt AI-based repurposing strategies to deliver innovative treatments more efficiently.
• Advanced AI Algorithms: Graph neural networks, natural language processing, and integrated multi-omics data analytics are dramatically improving the accuracy of drug-disease association predictions.
• Cost-Efficiency and Reduced Time to Market: By leveraging existing pharmacological data and histories, AI reduces costly clinical trial phases and accelerates candidate candidate identification.

Segment Insights: Where AI Is Making the Biggest Impact

The Polaris Market Research report highlights key segments that are shaping growth across the AI in Drug Repurposing landscape.

Drug Type:

• Small Molecules Lead the Market: Due to abundant clinical data and established regulatory pathways, small molecule drugs remain the dominant segment, with AI tools maximizing repurposing success rates.
• Biologics & Vaccines: With AI’s growing capability to decode complex protein interactions, biologics are poised for accelerated repurposing trajectories.

Therapeutic Areas:

• Oncology Dominates: Cancer remains the top application area for AI repurposing efforts, given the volume of clinical research and the urgency for innovative treatments.
• Neurology & Rare Diseases: Growing R&D spend and unmet medical needs in neurological disorders are driving significant AI adoption for identifying new therapeutic opportunities.

Deployment Mode & End Users:

• Cloud-based Solutions: Offering scalable compute and collaborative capabilities, cloud deployments are preferred for handling extensive biomedical datasets.
• Pharmaceutical & Biotechnology Firms: Pharma companies remain the primary adopters of AI repurposing platforms, leveraging them to optimize discovery-to-market timelines.

Get the Market Insights You Need — Download Your Free Sample Today

https://www.polarismarketresearch.com/industry-analysis/ai-in-drug-repurposing-market/request-for-sample

Regional Growth: North America Leads, Asia Pacific on Fast Track

The report identifies North America as the leading regional market, driven by strong collaborations between AI innovators, biotech firms, and academic research institutions. The U.S., in particular, continues to dominate due to deep digital infrastructure, extensive clinical databases, and expansive investment in AI research platforms.

Meanwhile, Asia Pacific is poised for rapid expansion, with countries like South Korea making substantial government investments in AI-driven drug discovery and repurposing initiatives. Collaborative ventures between global pharmaceutical leaders and regional AI startups are expanding market penetration across emerging markets.

Innovation & Strategic Partnerships Fuel Future Growth

The competitive landscape in the AI in Drug Repurposing market reflects vigorous innovation — from autonomous machine learning platforms that parse biological data at unprecedented scales to cross-disciplinary alliances that unify computational biology with traditional pharmaceutical expertise.

Strategic collaborations between AI developers and pharmaceutical giants are increasing, enabling deeper exploration into drug repurposing avenues that were previously unattainable due to time and resource constraints. By integrating AI insights with clinical real-world evidence, stakeholders are witnessing improved success rates in repurposing candidates and enhanced patient outcomes.

Looking Ahead: AI’s Transformative Path in Healthcare R&D

As the global AI in Drug Repurposing market continues to evolve, healthcare providers, life science researchers, and industry pioneers are redefining the pathways to innovation. The fusion of AI’s computational power with drug repurposing strategies represents a paradigm shift — one that dramatically accelerates therapeutic discovery while delivering cost-effective solutions for complex diseases.